These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29146743)

  • 1. Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis.
    Kavanaugh A; van Vollenhoven RF; Fleischmann R; Emery P; Sainsbury I; Florentinus S; Chen S; Guérette B; Kupper H; Smolen JS
    Ann Rheum Dis; 2018 Feb; 77(2):289-292. PubMed ID: 29146743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study.
    Kavanaugh A; Fleischmann RM; Emery P; Kupper H; Redden L; Guerette B; Santra S; Smolen JS
    Ann Rheum Dis; 2013 Jan; 72(1):64-71. PubMed ID: 22562973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate.
    Tkacz J; Gharaibeh M; DeYoung KH; Wilson K; Collier D; Oko-Osi H
    J Manag Care Spec Pharm; 2020 Mar; 26(3):285-294. PubMed ID: 32105179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study.
    Hoff M; Kvien TK; Kälvesten J; Elden A; Kavanaugh A; Haugeberg G
    BMC Musculoskelet Disord; 2011 Feb; 12():54. PubMed ID: 21352592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study.
    Fleischmann R; Swierkot J; Penn SK; Durez P; Bessette L; Bu X; Khan N; Li Y; Peterfy CG; Tanaka Y; Mysler E
    RMD Open; 2024 May; 10(2):. PubMed ID: 38806190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry.
    Favalli EG; Becciolini A; Biggioggero M; Bertoldi I; Crotti C; Raimondo MG; Marchesoni A
    Drug Des Devel Ther; 2018; 12():1421-1429. PubMed ID: 29872265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial.
    Tamai H; Ikeda K; Miyamoto T; Taguchi H; Kuo CF; Shin K; Hirata S; Okano Y; Sato S; Yasuoka H; Kuwana M; Ishii T; Kameda H; Kojima T; Taninaga T; Mori M; Miyagishi H; Sato Y; Tsai WC; Takeuchi T; Kaneko Y;
    Lancet Rheumatol; 2023 Apr; 5(4):e215-e224. PubMed ID: 38251524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate.
    Smolen JS; van der Heijde DM; Keystone EC; van Vollenhoven RF; Goldring MB; Guérette B; Cifaldi MA; Chen N; Liu S; Landewé RB
    Ann Rheum Dis; 2013 Jul; 72(7):1156-62. PubMed ID: 22915617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation.
    Kirkham BW; Wasko MC; Hsia EC; Fleischmann RM; Genovese MC; Matteson EL; Liu H; Rahman MU
    Ann Rheum Dis; 2014 Jan; 73(1):161-9. PubMed ID: 23300117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis.
    Landewé R; Smolen JS; Florentinus S; Chen S; Guérette B; van der Heijde D
    Arthritis Res Ther; 2015 May; 17(1):133. PubMed ID: 25994819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of adalimumab combined with Tripterygium wilfordii Hook F in the treatment of patient with rheumatoid arthritis: A multicenter, open-label, randomized-controlled trial.
    Luo F; Gau SY; Wu YX; Liao HL; Tang F; Zhong Q; Huang Y; Hou L; Liu ZQ; Cai JL; Cao YP; Lu DM; An Y; Lan WY; Liu C; Chen CM; Jia ET; Yao XM; Wei JC; Ma WK
    Int J Rheum Dis; 2024 Jan; 27(1):e15031. PubMed ID: 38287544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
    Cohen SB; van Vollenhoven RF; Winthrop KL; Zerbini CAF; Tanaka Y; Bessette L; Zhang Y; Khan N; Hendrickson B; Enejosa JV; Burmester GR
    Ann Rheum Dis; 2021 Mar; 80(3):304-311. PubMed ID: 33115760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?
    Emery P; Kavanaugh A; Bao Y; Ganguli A; Mulani P
    Ann Rheum Dis; 2015 Dec; 74(12):2165-74. PubMed ID: 25139667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study.
    Hoff M; Kvien TK; Kälvesten J; Elden A; Haugeberg G
    Ann Rheum Dis; 2009 Jul; 68(7):1171-6. PubMed ID: 18801760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases.
    Welzel T; Golhen K; Atkinson A; Gotta V; Ternant D; Kuemmerle-Deschner JB; Michler C; Koch G; van den Anker JN; Pfister M; Woerner A
    Pediatr Rheumatol Online J; 2024 Jan; 22(1):5. PubMed ID: 38167019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upadacitinib
    Pavelka K; Szekanecz Z; Damjanov N; Anić B; Tomšič M; Mazurov V; Maksimovic M; Nagy O; Świerkot J; Petranova T; Veldi T; Baranauskaitė A; Codreanu C; Andersone D; Fleischmann R
    Drugs Context; 2020; 9():. PubMed ID: 33123205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research.
    Salliot C; van der Heijde D
    Ann Rheum Dis; 2009 Jul; 68(7):1100-4. PubMed ID: 19060002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sexual dysfunction in male patients treated with methorexate for arthritis: Analysis of the IIEF5 questionnaire and hormonal status.
    Natalucci F; Bisseron S; Sokolova T; Avramovska A; Maiter D; Durez P
    Joint Bone Spine; 2024 Jul; 91(4):105716. PubMed ID: 38447696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses.
    Tanaka Y; Takeuchi T; Atsumi T; Combe BG; Aletaha D; Kaise T; Rajendran V
    Rheumatol Ther; 2023 Dec; 10(6):1399-1415. PubMed ID: 37668865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review.
    Sherbini AA; Sharma SD; Gwinnutt JM; Hyrich KL; Verstappen SMM
    Rheumatology (Oxford); 2021 Sep; 60(9):4001-4017. PubMed ID: 33909898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.